Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 1:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 715 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pulmonary Cystic Fibrosis Clear all
Completed Phase 4 Interventional Results available

Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis

NCT02504827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ceftazidime/avibactam
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 1, 2026, 1:02 AM EDT
Terminated Phase 2 Interventional Results available

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

NCT04059094
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
BI 1265162, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Orlando, Florida • Indianapolis, Indiana • Chapel Hill, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 1, 2026, 1:02 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis

NCT00006273
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 10 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1996
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 1, 2026, 1:02 AM EDT
Completed No phase listed Observational

Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)

NCT06506773
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
Up to 6 Months
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
22
States / cities
St. Petersburg, Florida • Boise, Idaho • Chicago, Illinois + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 1, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

NCT03489629
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Trimethoprim Sulfamethoxazole (TMP/SMX), Minocycline, Mupirocin, Chlorhexidine Gluconate, Environmental Decontamination
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
2 Years to 45 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 1, 2026, 1:02 AM EDT
Completed Phase 1 Interventional

A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device

NCT02141191
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
inhaled hypertonic saline (7%)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 1, 2026, 1:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

NCT03140527
View directory record Official record
Conditions
Healthy Volunteer, Cystic Fibrosis
Interventions
PTI-801, Placebo, PTI-808
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
33
States / cities
Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 1, 2026, 1:02 AM EDT
Completed No phase listed Observational

Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)

NCT02039986
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 1, 2026, 1:02 AM EDT
Completed Not applicable Interventional

Implementation of a Clinical Tool to Improve Waitlist Mortality in Patients With Cystic Fibrosis

NCT04687475
View directory record Official record
Conditions
Cystic Fibrosis, Lung Transplant; Complications
Interventions
Clinical Tool (Mobile Spirometry and Survey)
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 1, 2026, 1:02 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

NCT03227471
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
IVA, TEZ/IVA, VX-445, Matched Placebo, TEZ, VX-561
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 1, 2026, 1:02 AM EDT
Terminated Phase 4 Interventional

Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis

NCT05561764
View directory record Official record
Conditions
Cystic Fibrosis, Pneumonia, Bacterial
Interventions
Imipenem/Cilastatin/Relebactam
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
12 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Hartford, Connecticut • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 1, 2026, 1:02 AM EDT
Completed Phase 2 Interventional

Glutamine Supplementation in Cystic Fibrosis

NCT01051999
View directory record Official record
Conditions
Cystic Fibrosis, Immune Function
Interventions
Glutamine, L-alanine
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Oct 1, 2026, 1:02 AM EDT
Suspended Not applicable Interventional

A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis

NCT00005110
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Salmeterol, Albuterol
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 1, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 1, 2026, 1:02 AM EDT
Completed Not applicable Interventional

Saline Hypertonic in Preschoolers

NCT02378467
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
7% Hypertonic Saline (HS), 0.9% Isotonic Saline (IS)
Drug
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
3 Years to 5 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 1, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation

NCT01161537
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-770, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 1, 2026, 1:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

NCT02679729
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZD5634 for inhalation, AZD5634 for infusion, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 1, 2026, 1:02 AM EDT
Recruiting No phase listed Observational

Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)

NCT06837181
View directory record Official record
Conditions
Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes, Diabetes, Retinopathy, Neuropathy, Nephropathy, Blood Pressure, Cardiovascular Risk, Microvascular
Interventions
observational study
Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 1, 2026, 1:02 AM EDT
Completed Not applicable Interventional Results available

Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients

NCT01784419
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ivacaftor, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 1, 2026, 1:02 AM EDT
Active, not recruiting No phase listed Observational

Feasibility and Acceptance of SonoHeal for Airway Clearance and Preliminary Comparison With the Standard of Care

NCT07568119
View directory record Official record
Conditions
Cystic Fibrosis (CF), Non Cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Airway clearance therapy through acoustic oscillations
Device
Lead sponsor
Cognita Labs LLC
Industry
Eligibility
11 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 1, 2026, 1:02 AM EDT
Completed Phase 3 Interventional Results available

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

NCT03125395
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 1, 2026, 1:02 AM EDT
Completed Not applicable Interventional

Effects of a Partially Supervised Conditioning Program in CF

NCT01744561
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Exercise Intervention
Behavioral
Lead sponsor
Wuerzburg University Hospital
Other
Eligibility
12 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 1, 2026, 1:02 AM EDT
Completed No phase listed Observational

Fecal Calprotectin in Cystic Fibrosis

NCT00863694
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Month and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 1, 2026, 1:02 AM EDT
Completed No phase listed Observational

Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung

NCT01805713
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
6 Months and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 1, 2026, 1:02 AM EDT